M. Docteur VINCENT GERMAIN

Bibliographie

• Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry

  2024

  ArticleJournal of Infection

• Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study

  2021

  ArticleArthritis & rheumatology

• Role of stress in the development of rheumatoid arthritis: a case–control study

  2021

  ArticleRheumatology

• A guide to LIGO–Virgo detector noise and extraction of transient gravitational-wave signals

  2020

  ArticleClass.Quant.Grav.

• Switch de l’infliximal original pour le CT-P13 en vie réelle : le poids de l’acceptation du patient

  2019

  ArticleRevue du Rhumatisme

• Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

  2019

  ArticleSeminars in Arthritis and Rheumatism

• Constraints on cosmic strings using data from the first Advanced LIGO observing run

  2018

  ArticlePhys.Rev.D

• Full Band All-sky Search for Periodic Gravitational Waves in the O1 LIGO Data

  2018

  ArticlePhys.Rev.D

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

• CABINET DU DR VINCENT GERMAIN

  CENTRE DE RHUMATOLOGIE DES PYRENEES — 7 RUE DU PONT LONG, 64121 Serres-Castet

  Libéral
  231 m

  © OpenStreetMap · Photos Wikimedia Commons (CC)

  📷 Street View ↗🗺️ Maps ↗OSM ↗

• CENTRE HOSPITALIER DE PAU

  4 Boulevard HAUTERIVE, 64046 Pau

  ☎ 0559924848Hospitalier🏥 Centre CH ↗🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Automated trapping, assembly, and sorting with holographic optical tweezers

  Optics express · 2006

  📚 77 citations🎯 RCR 2.08🔓 Open Access
• 2

  Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study

  Arthritis & rheumatology (Hoboken, N.J.) · 2021

  📚 72 citations🎯 RCR 5.66Top 6% NIH

  Lire l'abstract Crossref ↓

  ObjectiveTo describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).MethodsA retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease.ResultsAmong the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5–13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1–4.5) and the median BVAS in the MEPO group was 2 (IQR 1–5). In patients receiving RTX, the median BVAS declined both at 6 months (median 1, IQR 0–4.5) and at 12 months (median 0, IQR 0–2), and the frequency of remission, partial response, treatment failure, and stopping treatment due to adverse events was 49%, 24%, 24%, and 3%, respectively. For the treatment of glucocorticoid (GC)–dependent asthma, patients who received MEPO had a much better GC‐sparing effect and overall response than did patients who received OMA. The frequency of remission, partial response, treatment failure, and stopping treatment due to adverse events was 15%, 33%, 48%, and 4%, respectively, in the OMA group and 78%, 10%, 8%, and 4%, respectively, in the MEPO group. Remission rates at 12 months were 76% and 82% among patients receiving MEPO at a doses of 100 mg and 300 mg, respectively.ConclusionThese results suggest that RTX could be effective in treating relapses of EGPA vasculitis. MEPO is highly effective with a good safety profile in patients with GC‐dependent asthma. Our data suggest that 100 mg MEPO monthly could be an acceptable dosage for first‐line therapy in selected instances of EGPA, recognizing, however, that this has not been compared to the validated dosage of 300 mg monthly.

• 3

  Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance

  Joint bone spine · 2018

  📚 61 citations🎯 RCR 3.56Top 13% NIH

Publications scientifiques (10) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Automated trapping, assembly, and sorting with holographic optical tweezers

  Collection2006Figshare

  We combine real-time feature recognition with holographic optical tweezers to automatically trap, assemble, and sort micron-sized colloidal particles. Closed loop control will enable new applications of optical micromani

• Automated trapping, assembly, and sorting with holographic optical tweezers

  Collection2006Figshare

  We combine real-time feature recognition with holographic optical tweezers to automatically trap, assemble, and sort micron-sized colloidal particles. Closed loop control will enable new applications of optical micromani

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche